S-1/A: Nuwellis Announces Proposed Securities Offering

Nuwellis, Inc. is conducting a reasonable best efforts offering of common stock and warrants to raise capital for working capital and general corporate purposes.

Summary

• The company is offering up to 6,578,948 shares of common stock or pre-funded warrants.
• The offering includes Series C common warrants to purchase up to 19,736,844 shares and Series D common warrants to purchase up to 6,578,948 shares.
• The assumed combined public offering price is $0.76 per share and accompanying warrants.
• The company estimates net proceeds of approximately $4.4 million if the offering is fully subscribed.
• The offering is on a reasonable best efforts basis with no minimum amount required to close.
• The company intends to use proceeds for working capital and general corporate purposes, including potential acquisitions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly dilutive capital raise necessitated by the company's ongoing operating losses and limited cash runway, reflecting significant financial pressure.

Positives

• The offering provides necessary capital to fund operations through the end of fiscal year 2026.
• The company has received 510(k) clearance for the Aquadex SmartFlow system for pediatric patients weighing 20kg or more.
• A dedicated Category III CPT code (0692T) for Therapeutic Ultrafiltration provides additional reimbursement potential in outpatient settings.

Negatives

• The company has incurred operating losses since inception, with an accumulated deficit of $316.3 million as of December 31, 2025.
• The company is dependent on a single product, the Aquadex System, for its near-term revenue.
• The company has identified two material weaknesses in its internal control over financial reporting.
• The company relies on a single-source manufacturer, KDI Precision Manufacturing, for its primary products.
• The offering is highly dilutive to existing shareholders.

Risks

• The company may not be able to continue as a going concern if additional capital is not raised.
• The company faces intense competition from established medical device and pharmaceutical companies.
• The company is subject to significant regulatory oversight and potential enforcement actions by the FDA.
• The company's reliance on sole-source suppliers makes it vulnerable to supply chain disruptions.
• The company's common stock is subject to potential delisting from Nasdaq if it fails to meet continued listing requirements.
• The company is subject to litigation risks that could adversely affect its financial condition.

Future Outlook

The company intends to use the proceeds to fund operations through the end of fiscal year 2026 and for general corporate purposes, including potential acquisitions. The company's ability to continue as a going concern is dependent on raising additional capital.

Management Comments

• Management emphasizes the focus on commercializing the Aquadex System.
• Management acknowledges the need for additional capital to fund operations through 2026.
• Management notes the strategic importance of the Rendiatech acquisition for automated kidney function monitoring.

Industry Context

StockSavvy.ai notes that Nuwellis operates in the highly competitive medical device space, specifically targeting fluid overload. The company's reliance on a single product and its history of operating losses are common challenges for small-cap medical technology firms, which often require frequent capital raises to sustain R&D and commercialization efforts.

Comparison to Industry Standards

• The company's reliance on a single product (Aquadex) is higher than diversified medical device peers like Medtronic or Baxter.
• The company's financial position, characterized by recurring losses and reliance on equity financing, is typical for early-stage, smaller reporting medical technology companies.
• The use of pre-funded warrants and common warrants is a standard mechanism for small-cap companies to raise capital while managing immediate dilution concerns.

Management Changes

Corporate Governance

Legal Proceedings

• Settled a lawsuit with E.F. Hutton & Co. on April 24, 2026, regarding a breach of engagement letter.

Related Party Transactions

• None disclosed beyond standard executive compensation and employment agreements.

Stakeholder Impact

• Existing shareholders face significant dilution from the issuance of new shares and warrants.
• Investors in the offering face risks related to the company's financial stability and potential delisting.
• Creditors may be impacted by the company's ongoing operating losses and capital requirements.

Next Steps

• Obtain Warrant Stockholder Approval for the exercise of common warrants.
• Complete the offering by June 30, 2026.
• Remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company is in a precarious financial position, relying on continuous capital raises to fund operations. While the Aquadex system has a niche market, the high dilution and ongoing losses make this a speculative investment suitable only for those with a high risk tolerance.

Keywords

Nuwellis, Aquadex, Ultrafiltration, Medical Devices, Securities Offering, Fluid Overload, Capital Raise